## Eiichi Araki

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4341974/publications.pdf

Version: 2024-02-01

87886 32838 10,399 121 38 100 citations h-index g-index papers 134 134 134 9475 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice, 1995, 28, 103-117.	2.8	2,814
2	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	2.4	1,206
3	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigation, 2012, 3, 39-40.	2.4	731
4	Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 2010, 1, 2-20.	1.4	322
5	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	1.4	266
6	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 951-964.	11.4	228
7	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2291-2301.	3.6	225
8	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
9	Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 2006, 55, 120-7.	0.6	215
10	Statins Activate Peroxisome Proliferator-Activated Receptor $\hat{l}^3$ Through Extracellular Signal-Regulated Kinase $1/2$ and p38 Mitogen-Activated Protein Kinaseâ $\in$ "Dependent Cyclooxygenase-2 Expression in Macrophages. Circulation Research, 2007, 100, 1442-1451.	4.5	214
11	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetology International, 2012, 3, 8-10.	1.4	202
12	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq0 0 C	) rgBT/Ove	erlock 10 Tf 50
13	Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes. Diabetes Care, 2003, 26, 1507-1512.	8.6	173
14	SIRT7 Controls Hepatic Lipid Metabolism by Regulating the Ubiquitin-Proteasome Pathway. Cell Metabolism, 2014, 19, 712-721.	16.2	173
15	Impact of Endoplasmic Reticulum Stress Pathway on Pancreatic $\hat{l}^2$ -Cells and Diabetes Mellitus. Experimental Biology and Medicine, 2003, 228, 1213-1217.	2.4	161
16	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	2.4	159
17	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	2.4	158
18	Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016, 249, 36-43.	0.8	146

#	Article	IF	CITATIONS
19	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	8.6	146
20	Efficacy and safety of pemafibrate (K-877), aÂselective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. Journal of Clinical Lipidology, 2018, 12, 173-184.	1.5	127
21	Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 2018, 41, 538-546.	8.6	122
22	Oxidative stress: A cause and therapeutic target of diabetic complications. Journal of Diabetes Investigation, 2010, 1, 90-96.	2.4	109
23	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor $\hat{l}^{\pm}$ modulator (SPPARM $\hat{l}^{\pm}$ ), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017, 261, 144-152.	0.8	101
24	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Atherosclerosis and Thrombosis, 2018, 25, 521-538.	2.0	97
25	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. Journal of Diabetes Investigation, 2017, 8, 397-410.	2.4	95
26	Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Research and Clinical Practice, 2000, 48, 201-210.	2.8	91
27	Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. PLoS ONE, 2016, 11, e0158619.	2.5	85
28	Enhanced expression of PDX-1 and Ngn3 by exendin-4 during $\hat{l}^2$ cell regeneration in STZ-treated mice. Biochemical and Biophysical Research Communications, 2005, 327, 1170-1178.	2.1	84
29	TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochemical and Biophysical Research Communications, 2009, 379, 43-48.	2.1	74
30	Mild Electrical Stimulation with Heat Shock Ameliorates Insulin Resistance via Enhanced Insulin Signaling. PLoS ONE, 2008, 3, e4068.	2.5	66
31	FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism. Nature Communications, 2019, 10, 1582.	12.8	57
32	Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and obese KK-Ay mice. Journal of Clinical Biochemistry and Nutrition, 2016, 59, 207-214.	1.4	53
33	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences, 2019, 20, 706.	4.1	53
34	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001â€"2010: report of Committee on Causes of Death in Diabetes Mellitus. Diabetology International, 2017, 8, 117-136.	1.4	49
35	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Journal of Diabetes Investigation, 2017, 8, 123-125.	2.4	48
36	Hyperthermia With Mild Electrical Stimulation Protects Pancreatic $\hat{l}^2$ -Cells From Cell Stresses and Apoptosis. Diabetes, 2012, 61, 838-847.	0.6	43

#	Article	IF	Citations
37	Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16â€week doubleâ€blind treatment period. Journal of Diabetes Investigation, 2016, 7, 555-564.	2.4	42
38	Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. Journal of Diabetes Investigation, 2015, 6, 137-139.	2.4	41
39	Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor-Î <sup>3</sup> in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1268-1275.	2.4	40
40	Longâ€term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT &lt; /scp&gt;â€2 study): 52â€week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.</scp>	4.4	38
41	Identification of microRNA that represses IRS-1 expression in liver. PLoS ONE, 2018, 13, e0191553.	2.5	37
42	Nifedipine Induces Peroxisome Proliferator-Activated Receptor- $\hat{I}^3$ Activation in Macrophages and Suppresses the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1598-1605.	2.4	36
43	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. Journal of Clinical Lipidology, 2018, 12, 1267-1279.e4.	1.5	35
44	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52â€week data from the PROVIDE study. Diabetes, Obesity and Metabolism, 2019, 21, 1737-1744.	4.4	35
45	Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. Journal of Diabetes Investigation, 2017, 8, 750-761.	2.4	33
46	Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. Journal of Clinical Biochemistry and Nutrition, 2016, 58, 135-140.	1.4	32
47	Effects of a novel selective peroxisome proliferatorâ€activated receptorâ€Î± modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Journal of Diabetes Investigation, 2018, 9, 1323-1332.	2.4	32
48	Efficacy and safety of dapagliflozin over 1 year as addâ€on to insulin therapy in <scp>J</scp> apanese patients with type 2 diabetes: the <scp>DAISY</scp> (Dapagliflozin Added to patients under InSulin) Tj ETQq0 0	O angaBT /	Ove <b>do</b> ck 10 Tf
49	Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovascular Diabetology, 2013, 12, 160.	6.8	27
50	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences, 2019, 20, 5537.	4.1	27
51	Mild Electrical Stimulation Increases Ubiquitinated Proteins and Hsp72 in A549 Cells via Attenuation of Proteasomal Degradation. Journal of Pharmacological Sciences, 2008, 108, 222-226.	2.5	25
52	An acylic polyisoprenoid derivative, geranylgeranylacetone protects against visceral adiposity and insulin resistance in high-fat-fed mice. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E764-E771.	3.5	25
53	Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor- $\hat{l}^3$ activation. Biochemical and Biophysical Research Communications, 2015, 457, 23-30.	2.1	24
54	Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials. EBioMedicine, 2014, 1, 80-89.	6.1	22

#	Article	IF	Citations
55	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICTâ€5): 52â€week results from a randomized, openâ€label, phase III clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 540-548.	4.4	22
56	<scp>Longâ€term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp> â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	4.4	21
57	Brown adipocyte-derived exosomal miR-132-3p suppress hepatic Srebf1 expression and thereby attenuate expression of lipogenic genes. Biochemical and Biophysical Research Communications, 2020, 530, 500-507.	2.1	20
58	Insulin receptor activation through its accumulation in lipid rafts by mild electrical stress. Journal of Cellular Physiology, 2013, 228, 439-446.	4.1	19
59	A $1\hat{a}\in\mathbf{y}$ ear, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal $\hat{a}\in\mathbf{u}$ bolus insulin therapy (Kumamoto Insulin Degludec Observational study). Journal of Diabetes Investigation, 2016, 7, 703-710.	2.4	19
60	Impaired balance is related to the progression of diabetic complications in both young and older adults. Journal of Diabetes and Its Complications, 2017, 31, 1275-1282.	2.3	19
61	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13–p12 in Japanese. Journal of Human Genetics, 2004, 49, 629-634.	2.3	18
62	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 876-882.	4.4	18
63	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized doubleâ€blind placeboâ€controlled clinical trials. Cardiovascular Diabetology, 2021, 20, 96.	6.8	16
64	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes ― A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society ―. Circulation Journal, 2020, 85, 82-125.	1.6	16
65	Superior efficacy with a fixedâ€ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulinâ€naà ve Japanese patients with type 2 diabetes in a phase 3, openâ€label, randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 2674-2683.	4.4	15
66	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	2.8	15
67	Heat shock treatment with mild electrical stimulation safely reduced inflammatory markers in healthy male subjects. Obesity Research and Clinical Practice, 2010, 4, e101-e109.	1.8	14
68	Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice. Antioxidants and Redox Signaling, 2021, 34, 1245-1259.	5.4	14
69	Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: Impact of the suppression of nuclear translocation of ERK1/2. Atherosclerosis, 2007, 191, 22-32.	0.8	13
70	Mild Electrical Stimulation Increases Stress Resistance and Suppresses Fat Accumulation via Activation of LKB1-AMPK Signaling Pathway in C. elegans. PLoS ONE, 2014, 9, e114690.	2.5	13
71	Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 179-184.	2.4	12
72	Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARÎ <sup>3</sup> . Atherosclerosis, 2019, 286, 30-39.	0.8	12

#	Article	IF	CITATIONS
73	Impact of hepatic HSP72 on insulin signaling. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E305-E318.	3.5	12
74	Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes. Journal of Diabetes Investigation, 2019, 10, 521-530.	2.4	11
75	Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial. Scientific Reports, 2016, 6, 35690.	3.3	10
76	Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naA¬ve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. Endocrine Journal, 2019, 66, 745-752.	1.6	10
77	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate. Journal of Atherosclerosis and Thrombosis, 2021, 28, 974-996.	2.0	10
78	Mechanismâ€based antioxidant therapies promise to prevent diabetic complications?. Journal of Diabetes Investigation, 2013, 4, 105-107.	2.4	9
79	Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochemical and Biophysical Research Communications, 2020, 524, 8-15.	2.1	9
80	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1279-1282.	4.4	8
81	The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. BMC Endocrine Disorders, 2018, 18, 4.	2.2	8
82	A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after anti-tumor necrosis factor therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140117.	0.5	8
83	Comparison of the efficacy of sitagliptin and glimepiride doseâ€up in <scp>J</scp> apanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. Journal of Diabetes Investigation, 2014, 5, 320-326.	2.4	7
84	Baseline Plasma Aldosterone Level and Renin Activity Allowing Omission of Confirmatory Testing in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1990-e1998.	3.6	7
85	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the <scp>PIONEER</scp> 1, 3, 4 and 8 trials. Diabetes, Obesity and Metabolism, 2021, 23, 2785-2794.	4.4	7
86	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International, 2016, 7, 327-330.	1.4	6
87	Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus. Endocrine Journal, 2019, 66, 253-258.	1.6	6
88	Clinical Features of Patients With Acute Aortic Dissection After an Earthquake: Experience from the Kumamoto Earthquake 2016. American Journal of Hypertension, 2020, 33, 261-268.	2.0	6
89	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	1.4	6
90	Longâ€term (52â€week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the ⟨scp⟩DEPICT⟨/scp⟩â€2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1496-1504.	4.4	6

#	Article	IF	Citations
91	Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160003.	0.5	6
92	Clinical Features of Disaster-Associated Direct Deaths during Recent Inland Earthquakes in Japan. Tohoku Journal of Experimental Medicine, 2020, 251, 169-173.	1.2	5
93	New classification and diagnostic criteria for insulin resistance syndrome. Endocrine Journal, 2022, 69, 107-113.	1.6	5
94	New classification and diagnostic criteria for insulin resistance syndrome. Diabetology International, 2022, 13, 337-343.	1.4	5
95	Predictors of coronary heart disease in Japanese patients with type 2 diabetes: Screening for coronary artery stenosis using multidetector computed tomography. Journal of Diabetes Investigation, 2010, 1, 50-55.	2.4	4
96	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy. Diabetes Therapy, 2019, 10, 1347-1356.	2.5	4
97	Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets. Journal of Clinical Medicine, 2019, 8, 674.	2.4	4
98	Impact of tissue macrophage proliferation on peripheral and systemic insulin resistance in obese mice with diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001578.	2.8	4
99	A homogeneous assay to determine high-density lipoprotein subclass cholesterol in serum. Analytical Biochemistry, 2021, 613, 114019.	2.4	4
100	Rapid and dramatic glucose″owering effect of bromocriptine in an inadequately controlled typeÂ2 diabetes patient with prolactinoma. Journal of Diabetes Investigation, 2021, 12, 668-671.	2.4	3
101	Clinical profiles of hyperglycemic crises: A singleâ€center retrospective study from Japan. Journal of Diabetes Investigation, 2021, 12, 1359-1366.	2.4	3
102	Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. Endocrine Connections, 2021, 10, 521-533.	1.9	3
103	Atypical pituitary abscess lacking rim enhancement and diffusion restriction with an unusual organism, <i>Moraxella catarrhalis</i> ): A case report and review of the literature., 2021, 12, 617.		3
104	Thiazolidinedioneâ€independent activation of peroxisome proliferatorâ€activated receptor γ is a potential target for diabetic macrovascular complications. Journal of Diabetes Investigation, 2012, 3, 11-23.	2.4	2
105	Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters. Tohoku Journal of Experimental Medicine, 2022, 256, 175-185.	1.2	2
106	Dietary intake and physical activity in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 8). Diabetology International, 2022, 13, 344-357.	1.4	2
107	The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetesâ€"data from the Japan cohort. Diabetology International, 2012, 3, 11-20.	1.4	1
108	Evaluation of a new device for measurement of hemoglobin A1c for Japanese subjects. Diabetology International, 2013, 4, 112-116.	1.4	1

#	Article	IF	CITATIONS
109	Efficacy of Pemafibrate on Atherogenic Dyslipidemia: Results of a Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Compared with Placebo. Atherosclerosis Supplements, 2018, 32, 25-26.	1.2	1
110	A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. World Neurosurgery, 2018, 119, 394-399.	1.3	1
111	Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3. Journal of Diabetes Investigation, 2018, 9, 1022-1024.	2.4	1
112	with Diabetes. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 419-426.	0.0	1
113	HbA <sub>1c</sub> : The lower the better?. Journal of Diabetes Investigation, 2011, 2, 45-47.	2.4	O
114	Cellular stress response pathways and diabetes mellitus. Diabetology International, 2015, 6, 239-242.	1.4	0
115	Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model. Scientific Reports, 2020, 10, 18719.	3.3	0
116	New perspectives on insulin therapy. Journal of Diabetes Investigation, 2020, 11, 795-797.	2.4	0
117	The Amount of Residual Incretin Regulates the Pancreatic $\hat{l}^2$ -cell Function and Glucose Homeostasis. Internal Medicine, 2021, 60, 1433-1442.	0.7	O
118	Abstract 12384: Novel Approach to Residual Risk, K-877, a Potent and Selective PPAR- $\hat{l}\pm$ Modulator (SPPARM $\hat{l}\pm$ ), Added-on to Pitavastatin in Japanese Patients With Dyslipidemia. Circulation, 2015, 132, .	1.6	0
119	8. Recent Advances in the Treatment of Diabetes. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1865-1873.	0.0	0
120	ç³–å°¿ç—…è™ç™,ã,¬ã,ãf‰ãf©ã,ãf³2019. The Journal of the Japanese Society of Internal Medicine, 2020, 109, °	9 <b>459</b> 50.	0
121	Questionnaire Survey Regarding Troubles and Concerns Related to Clinical Research Based on the Clinical Trial Act for Clinicians and Academics. Kurume Medical Journal, 2021, , .	0.1	0